As the roles of nurse practitioners and physician assistants continue to evolve, efforts are being made to integrate a NP/PA model into the hepatology and liver transplant field.
Prevalence of alcoholic fatty liver disease remained relatively unchanged from 2001 to 2016, but alcoholic fatty liver disease with fibrosis stage 2 and 3 or greater increased significantly.
Investigators sought to categorize hepatitis C virus infections in HIV-positive MSM as either domestically or internationally acquired and evaluate how this classification changed over time.
A team of investigators sought to identify the independent effects of hyperlipidemia and statin exposure on mortality, hepatic decompensation, and hepatocellular carcinoma in individuals with cirrhosis.
Universal healthcare screening at the first clinical encounter of pregnancy was found to be cost-effective and improved health outcomes in women diagnosed with HCV and identification of HCV exposure in neonates.
Topline data from the Phase 3 STELLAR-4 trial showed that selonsertib, an investigational treatment for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), was not associated with a significant improvement in fibrosis without worsening of NASH.
